{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:16:23Z","timestamp":1790424983278,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["PhD grant"],"award-info":[{"award-number":["PhD grant"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["PhD grant"],"award-info":[{"award-number":["PhD grant"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0D6817N"],"award-info":[{"award-number":["G0D6817N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP119cm0106501h0004"],"award-info":[{"award-number":["JP119cm0106501h0004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005683","name":"Kyoto University","doi-asserted-by":"publisher","award":["KAKENHI 15H05909"],"award-info":[{"award-number":["KAKENHI 15H05909"]}],"id":[{"id":"10.13039\/501100005683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["Vaast Leysen Leerstoel voor Infectieziekten in Ontwikkelingslanden"],"award-info":[{"award-number":["Vaast Leysen Leerstoel voor Infectieziekten in Ontwikkelingslanden"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-021-00409-3","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T21:23:32Z","timestamp":1612905812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis"],"prefix":"10.1038","volume":"11","author":[{"given":"Eline","family":"Boons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiane C.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1969-7974","authenticated-orcid":false,"given":"Tim","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya Maria","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-4189","authenticated-orcid":false,"given":"Maarten","family":"Jacquemyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Tamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achil\u00e9a","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8263-9902","authenticated-orcid":false,"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-8426","authenticated-orcid":false,"given":"Johan","family":"Van Weyenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-1153","authenticated-orcid":false,"given":"Dirk","family":"Daelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"409_CR1","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi, A. et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 28, 4177\u20134183 (2010).","journal-title":"J. Clin. Oncol."},{"key":"409_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"M Matsuoka","year":"2007","unstructured":"Matsuoka, M. & Jeang, K. T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 7, 270\u2013280 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"409_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fmicb.2018.00285","volume":"9","author":"S Fochi","year":"2018","unstructured":"Fochi, S., Mutascio, S., Bertazzoni, U., Zipeto, D. & Romanelli, M. G. HTLV deregulation of the NF-kappaB pathway: an update on tax and antisense proteins role. Front. Microbiol. 9, 285 (2018).","journal-title":"Front. Microbiol."},{"key":"409_CR4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1128\/JVI.72.2.1165-1170.1998","volume":"2","author":"CA P Pise-Masison","year":"1998","unstructured":"P Pise-Masison, C. A. et al. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J. Virol. 2, 1165\u20131170 (1998).","journal-title":"J. Virol."},{"key":"409_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","volume":"129","author":"T Watanabe","year":"2017","unstructured":"Watanabe, T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood 129, 1071\u20131081 (2017).","journal-title":"Blood"},{"key":"409_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/ncb1638","volume":"9","author":"M Kanai","year":"2007","unstructured":"Kanai, M. et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat. Cell Biol. 9, 1175\u20131183 (2007).","journal-title":"Nat. Cell Biol."},{"key":"409_CR7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ebiom.2015.07.041","volume":"2","author":"E Boons","year":"2015","unstructured":"Boons, E. et al. Human exportin-1 is a target for combined therapy of HIV and AIDS related lymphoma. EBioMedicine 2, 1102\u20131113 (2015).","journal-title":"EBioMedicine"},{"key":"409_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/leu.2012.219","volume":"27","author":"J Etch Etchin","year":"2013","unstructured":"Etch Etchin, J. et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27, 66\u201374 (2013).","journal-title":"Leukemia"},{"key":"409_CR9","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella, R. et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood 120, 4621\u20134634 (2012).","journal-title":"Blood"},{"key":"409_CR10","doi-asserted-by":"publisher","first-page":"14440","DOI":"10.1073\/pnas.212285299","volume":"99","author":"D Daelemans","year":"2002","unstructured":"Daelemans, D. et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl Acad. Sci. USA 99, 14440\u201314445 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"409_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.chembiol.2014.11.015","volume":"22","author":"JE Neggers","year":"2015","unstructured":"Neggers, J. E. et al. Identifying drug-target selectivity of small-molecule CRM1\/XPO1 inhibitors by CRISPR\/Cas9 genome editing. Chem. Biol. 22, 107\u2013116 (2015).","journal-title":"Chem. Biol."},{"key":"409_CR12","doi-asserted-by":"publisher","first-page":"9487","DOI":"10.1016\/j.bmc.2008.09.051","volume":"16","author":"T Van Neck","year":"2008","unstructured":"Van Neck, T. et al. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg. Med. Chem. 16, 9487\u20139497 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"409_CR13","doi-asserted-by":"publisher","first-page":"23414","DOI":"10.1074\/jbc.M600684200","volume":"281","author":"A Datta","year":"2006","unstructured":"Datta, A., Sinha-Datta, U., Dhillon, N. K., Buch, S. & Nicot, C. The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human macrophages. J. Biol. Chem. 281, 23414\u201323424 (2006).","journal-title":"J. Biol. Chem."},{"key":"409_CR14","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat. Genet. 47, 1304\u20131315 (2015).","journal-title":"Nat. Genet."},{"key":"409_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-52","volume":"10","author":"S Kinpara","year":"2013","unstructured":"Kinpara, S. et al. Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology 10, 52 (2013).","journal-title":"Retrovirology"},{"key":"409_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.126","volume":"7","author":"T Dierckx","year":"2017","unstructured":"Dierckx, T. et al. IFN-beta induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN-alpha in PBMCs of Adult T-cell Leukemia\/Lymphoma patients. Blood Cancer J. 7, e519 (2017).","journal-title":"Blood Cancer J."},{"key":"409_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1426423","volume":"7","author":"R Khouri","year":"2018","unstructured":"Khouri, R. et al. A genetic IFN\/STAT1\/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients. Oncoimmunology 7, e1426423 (2018).","journal-title":"Oncoimmunology"},{"key":"409_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1743-422X-9-171","volume":"9","author":"B Moens","year":"2012","unstructured":"Moens, B. et al. Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines. Virol. J. 9, 171 (2012).","journal-title":"Virol. J."},{"key":"409_CR19","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ijc.31922","volume":"144","author":"K Subramanian","year":"2019","unstructured":"Subramanian, K. et al. Decreased RORC expression and downstream signaling in HTLV-1-associated adult T-cell lymphoma\/leukemia uncovers an antiproliferative IL17 link: a potential target for immunotherapy? Int. J. Cancer 144, 1664\u20131675 (2019).","journal-title":"Int. J. Cancer"},{"key":"409_CR20","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1182\/blood-2006-07-036368","volume":"109","author":"JC Ramos","year":"2007","unstructured":"Ramos, J. C. et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia\/lymphoma. Blood 109, 3060\u20133068 (2007).","journal-title":"Blood"},{"key":"409_CR21","doi-asserted-by":"crossref","unstructured":"Rauch D. A. et al. Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma. Retrovirology 17, 27 (2020).","DOI":"10.1186\/s12977-020-00535-z"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00409-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:39:28Z","timestamp":1669909168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00409-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00409-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"1 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T. and Y.L. are employees of the manufacturer of selinexor (Karyopharm Therapeutics Inc). D.D., J.V.W., R.S., G.A., and T.D. are employees of KU Leuven. KU Leuven has a license agreement on XPO1 inhibitors (selinexor). Karyopharm and KU Leuven had no direct involvement in the interpretation of the results of this study. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"27"}}